Aerie Pharma to use DSM polymers to develop eye drug delivery tech

By Staff reporter

- Last updated on GMT

iStock/kwasny221
iStock/kwasny221
Aerie Pharmaceuticals Inc will use a DSM polymer technology to develop an implant to deliver AR-13154, its wet AMD drug candidate.

Under the collaboration the California, US-based drug firm will use polyesteramide polymer (PEA) technology – the degradation of which can be controlled – to make an injectable fibre that releases the active pharmaceutical ingredient (API) over an extended period.

The initial focus of the research will be AR-13154, a small molecule candidate that inhibits enzymes involved in the development of lesions characteristic of wet age-related macular degeneration (AMD).

However, the accord – financial terms of which were not disclosed – permits Aerie to apply the technology to other candidate compounds in its pipeline.

CEO Vicente Anido said: “Unlocking the potential of AR-13154 and related Aerie-owned compounds for the treatment of retinal diseases is the identification of the appropriate technology to achieve longer-term sustained delivery of our small molecules to the back of the eye​.”

Related news

Related products

Steridose

Optimizing vessel geometry for mag drive agitators

Steridose, Inc | 14-Sep-2017 | Technical / White Paper

The performance of a bottom mount magnetically driven agitator (mag drive mixer) is heavily dependent on its relationship with the vessel’s geometry, baffles,...

Related suppliers